Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. KROS
stocks logo

KROS

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
3.66M
+20.4%
-0.438
-61.55%
616.25K
-99.71%
-0.590
-116.3%
622.50K
-96.57%
-0.630
-17.11%
Estimates Revision
The market is revising Downward the revenue expectations for Keros Therapeutics, Inc. (KROS) for FY2025, with the revenue forecasts being adjusted by -2.13% over the past three months. During the same period, the stock price has changed by 30.02%.
Revenue Estimates for FY2025
Revise Downward
down Image
-2.13%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+133.74%
In Past 3 Month
Stock Price
Go Up
up Image
+30.02%
In Past 3 Month
Wall Street analysts forecast KROS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KROS is 20.80 USD with a low forecast of 16.00 USD and a high forecast of 27.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
Wall Street analysts forecast KROS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KROS is 20.80 USD with a low forecast of 16.00 USD and a high forecast of 27.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
4 Hold
0 Sell
Moderate Buy
Current: 20.270
sliders
Low
16.00
Averages
20.80
High
27.00
Current: 20.270
sliders
Low
16.00
Averages
20.80
High
27.00
BofA
Jason Zemansky
Neutral
maintain
$18 -> $19
2025-11-28
Reason
BofA
Jason Zemansky
Price Target
$18 -> $19
2025-11-28
maintain
Neutral
Reason
BofA analyst Jason Zemansky raised the firm's price target on Keros Therapeutics to $19 from $18 and keeps a Neutral rating on the shares after adjusting projections following the company's Q3 earnings update.
Oppenheimer
Andreas Argyrides
Outperform
maintain
$23 -> $27
2025-11-12
Reason
Oppenheimer
Andreas Argyrides
Price Target
$23 -> $27
2025-11-12
maintain
Outperform
Reason
Oppenheimer analyst Andreas Argyrides raised the firm's price target on Keros Therapeutics to $27 from $23 and keeps an Outperform rating on the shares following quarterly results and business update. The firm continues to anticipate the Phase 2 trial initiation for KER-065/DMD in Q1 2026, and is encouraged by recent additional Phase 1 data demonstrating continued durability and safe profile. As such, Oppenheimer sees KER-065 as a potentially differentiated TGF-beta inhibitor by avoiding BMP9/10 binding with no SAEs, and sees broader potential across other bone disorders.
Oppenheimer
Andreas Argyrides
Outperform
maintain
$23 -> $27
2025-11-07
Reason
Oppenheimer
Andreas Argyrides
Price Target
$23 -> $27
2025-11-07
maintain
Outperform
Reason
Oppenheimer analyst Andreas Argyrides raised the firm's price target on Keros Therapeutics to $27 from $23 and keeps an Outperform rating on the shares following quarterly results. The firm continues to anticipate the Phase 2 trial initiation for KER-065/DMD in Q1 2026, and is encouraged by recent additional Phase 1 data demonstrating continued durability and safe profile. As such, Oppenheimer sees KER-065 as a potentially differentiated TGF-beta inhibitor by avoiding BMP9/10 binding with no SAEs, and see broader potential across other bone disorders.
BofA
Jason Zemansky
Buy -> Neutral
downgrade
$32 -> $18
2025-06-10
Reason
BofA
Jason Zemansky
Price Target
$32 -> $18
2025-06-10
downgrade
Buy -> Neutral
Reason
BofA
Jason Zemansky
Buy
maintain
$33 -> $32
2025-05-27
Reason
BofA
Jason Zemansky
Price Target
$33 -> $32
2025-05-27
maintain
Buy
Reason
Scotiabank
Outperform
to
NULL
downgrade
$41 -> $26
2025-05-12
Reason
Scotiabank
Price Target
$41 -> $26
2025-05-12
downgrade
Outperform
to
NULL
Reason
Scotiabank lowered the firm's price target on Keros Therapeutics to $26 from $41 and keeps an Outperform rating on the shares. The firm is updating its price targets on biotechnology stocks following Q1 results, the analyst tells investors. The firm sees limited value-driving catalysts for the stock in the near-term.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Keros Therapeutics Inc (KROS.O) is -10.32, compared to its 5-year average forward P/E of -10.13. For a more detailed relative valuation and DCF analysis to assess Keros Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-10.13
Current PE
-10.32
Overvalued PE
-4.74
Undervalued PE
-15.52

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-2.41
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.54
Undervalued EV/EBITDA
-6.36

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
17293.45
Current PS
0.00
Overvalued PS
87224.83
Undervalued PS
-52637.92
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

KROS News & Events

Events Timeline

(ET)
2025-12-04
08:50:00
Latest Data Shows BMNU Borrow Rate Rises to 30.53%
select
2025-11-05 (ET)
2025-11-05
16:05:25
Keros Therapeutics Announces Q3 Earnings Per Share of 18 Cents, Below Consensus Estimate of 92 Cents
select
2025-10-20 (ET)
2025-10-20
06:05:46
Keros Therapeutics Plans to Buy Back $194.4 Million in Shares
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
4.0
11-29NASDAQ.COM
B of A Securities Keeps Neutral Rating on Keros Therapeutics (KROS)

  • Analyst Recommendation: B of A Securities has maintained a Neutral recommendation for Keros Therapeutics (NasdaqGM:KROS) as of November 28, 2025, with an average one-year price target of $23.72/share, indicating a potential upside of 35.59% from its current price of $17.49/share.

  • Financial Projections: Keros Therapeutics is projected to have an annual revenue of $22 million, reflecting a significant decrease of 91.07%, with a non-GAAP EPS forecast of -4.50.

  • Fund Sentiment: There are currently 312 funds reporting positions in Keros Therapeutics, with a slight increase in ownership and a bullish outlook indicated by a put/call ratio of 0.82.

  • Shareholder Activity: Notable shareholders include ADAR1 Capital Management, Madison Avenue Partners, and Western Standard, with varying changes in their shareholdings over the last quarter, reflecting mixed portfolio adjustments.

[object Object]
Preview
6.0
11-29Benzinga
B of A Securities Keeps Neutral Rating on Keros Therapeutics and Increases Price Target to $19

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make timely decisions in the stock market.

  • Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters, enhancing their trading strategies.

  • Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and experiences.

  • Market Winning Tools: The platform is designed to provide traders with the tools and information necessary to succeed in their trading endeavors.

[object Object]
Preview
8.0
11-19Newsfilter
Keros Therapeutics Reveals Initial Findings from Tender Offer

  • Tender Offer Announcement: Keros Therapeutics announced the preliminary results of its cash tender offer to repurchase up to 10,950,165 shares of its common stock at a price of $17.75 per share, totaling approximately $194.4 million, which expired on November 18, 2025.

  • Shares Tendered: Approximately 16,659,732 shares were validly tendered, exceeding the number Keros intended to repurchase, leading to a pro rata acceptance of shares.

  • Company Overview: Keros Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapeutics for disorders linked to TGF-ß protein signaling, with key products targeting neuromuscular diseases and cytopenias.

  • Forward-Looking Statements: The announcement includes forward-looking statements regarding the tender offer and potential risks, emphasizing that actual results may differ from expectations due to various uncertainties.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Keros Therapeutics Inc (KROS) stock price today?

The current price of KROS is 20.27 USD — it has increased 11.99 % in the last trading day.

arrow icon

What is Keros Therapeutics Inc (KROS)'s business?

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing novel therapeutics to treat a range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-B), family of proteins. Its lead product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, and in patients with myelofibrosis. Its product candidate, KER-012, is being developed for the treatment of pulmonary arterial hypertension, or PAH, and for the treatment of cardiovascular disorders. Its product candidate, KER-065, is being developed for the treatment of obesity and for the treatment of neuromuscular diseases. KER-050 is designed to raise red blood cell and platelet production by inhibiting the signaling of a subset of the TGF-B family of proteins to promote hematopoiesis.

arrow icon

What is the price predicton of KROS Stock?

Wall Street analysts forecast KROS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KROS is 20.80 USD with a low forecast of 16.00 USD and a high forecast of 27.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Keros Therapeutics Inc (KROS)'s revenue for the last quarter?

Keros Therapeutics Inc revenue for the last quarter amounts to 14.26M USD, increased 3575.77 % YoY.

arrow icon

What is Keros Therapeutics Inc (KROS)'s earnings per share (EPS) for the last quarter?

Keros Therapeutics Inc. EPS for the last quarter amounts to -0.18 USD, decreased -87.23 % YoY.

arrow icon

What changes have occurred in the market's expectations for Keros Therapeutics Inc (KROS)'s fundamentals?

The market is revising Downward the revenue expectations for Keros Therapeutics, Inc. (KROS) for FY2025, with the revenue forecasts being adjusted by -2.13% over the past three months. During the same period, the stock price has changed by 30.02%.
arrow icon

How many employees does Keros Therapeutics Inc (KROS). have?

Keros Therapeutics Inc (KROS) has 169 emplpoyees as of December 05 2025.

arrow icon

What is Keros Therapeutics Inc (KROS) market cap?

Today KROS has the market capitalization of 616.94M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free